美国 · 平台与数据 · The Motley Fool

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

来源：The Motley Fool · 美国 57 分钟前

详细摘要

Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.

在 The Motley Fool 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

详细摘要

推荐阅读

Budget airlines are going upscale with first-class seats and faster wifi

Amdocs director Yvette Kanouff acquires $100,800 in ordinary shares

Insider trades: Microsoft, Netflix, Boeing among notable names

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

Marvell’s 3 new directors hint at its biggest Lumentum risk

Market News

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

详细摘要

分享

推荐阅读

Budget airlines are going upscale with first-class seats and faster wifi

Amdocs director Yvette Kanouff acquires $100,800 in ordinary shares

Insider trades: Microsoft, Netflix, Boeing among notable names

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

Marvell’s 3 new directors hint at its biggest Lumentum risk

Market News